ETV Bharat / state

కొండపై నుంచి జారి ఇద్దరు మృతి - died

విజయనగరం జిల్లా నెల్లిమర్ల మండలం రామతీర్థంలో విషాదం చోటు చేసుకుంది. రామతీర్థం కొండ పైనుంచి పడి ఇద్దరు యువకులు మృతి చెందారు. శివరాత్రి సందర్భంగా ముగ్గురు యువకులు దర్శనానికి వెళ్లారు.

కొండపై నుంచి జారి ఇద్దరు మృతి

కొండపై నుంచి జారి ఇద్దరు మృతి

By

Published : Mar 6, 2019, 11:34 AM IST

విజయనగరం జిల్లా నెల్లిమర్ల మండలం రామతీర్థంలో విషాదం చోటు చేసుకుంది. రామతీర్థం కొండ పైనుంచి పడి ఇద్దరు యువకులు మృతి చెందారు. శివరాత్రి సందర్భంగా ముగ్గురు యువకులు దర్శనానికి వెళ్లారు. మృతులు విజయనగరం ప్రశాంతినగర్కు చెందిన కుమార్, సాయిగా గుర్తించారు. బాబామెట్టుకు చెందిన నాగరాజుకు తీవ్రగాయాల్యాయి. మెట్ల మార్గంలో కాకుండా కొండ వెనుక వైపు నుంచి వచ్చినట్లు పోలీసులు గుర్తించారు.

కొండపై నుంచి జారి ఇద్దరు మృతి

విజయనగరం జిల్లా నెల్లిమర్ల మండలం రామతీర్థంలో విషాదం చోటు చేసుకుంది. రామతీర్థం కొండ పైనుంచి పడి ఇద్దరు యువకులు మృతి చెందారు. శివరాత్రి సందర్భంగా ముగ్గురు యువకులు దర్శనానికి వెళ్లారు. మృతులు విజయనగరం ప్రశాంతినగర్కు చెందిన కుమార్, సాయిగా గుర్తించారు. బాబామెట్టుకు చెందిన నాగరాజుకు తీవ్రగాయాల్యాయి. మెట్ల మార్గంలో కాకుండా కొండ వెనుక వైపు నుంచి వచ్చినట్లు పోలీసులు గుర్తించారు.

కొండపై నుంచి జారి ఇద్దరు మృతి

RESTRICTION SUMMARY: PART MANDATORY ON-SCREEN CREDIT 'JOHNSON & JOHNSON'
SHOTLIST:
JOHNSON & JOHNSON - MANDATORY ON-SCREEN CREDIT 'JOHNSON & JOHNSON'
Date and Location Unknown
++MUTE FROM SOURCE++
1. Various of bottling of the nasal spray Spravato, Johnson & Johnson chemical version of ketamine
ASSOCIATED PRESS - AP CLIENTS ONLY
New York - 5 March 2019
2. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"Well, it's important for several reasons because ketamine is a kind of a breakthrough medication potentially. There are quite a few studies now that have shown that it works in depression. But it's not just the works in depression, it works in a completely different way to all other anti-depressants that we have to date."
3. Mann walking in his lab at Columbia University
4. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"Most antidepressant medications take weeks or a couple of months to work. It works in hours. Second, you know pretty much after the first or second dose of the medication whether or not it's going to help the patient. If they don't get better within the first couple of doses they're not going to respond to the medication. So you have a quick answer."
5. Mann talking with his colleagues in his lab
6. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"We're not entirely sure what particular properties of ketamine make it such a rapidly acting antidepressant. But one of the things that happens when you're depressed is that brain growth seems to slow and actually reverse. Parts of the brain actually get smaller and the longer you're depressed, the smaller those parts of the brain get. Ketamine seems to have the potential, as do other antidepressants, but it doesn't much more rapidly. It has the potential for reversing this brain growth deficiency and causing the brain to grow back towards the way it was."
7. Mann talking with his colleagues in his lab
8. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"So the most obvious side effect that people are aware of is that it's a bit like tripping. That's why people have used ketamine in other forms as a party drug. So you feel a bit unreal. The world around you feels a bit unreal. Things may seem a little distorted. You may become a little paranoid. There's definitely a sort of what we call a psychotic mimetic effect. You know, and in addition to that there are things that the patient doesn't experience but we detect. For example, it does produce a slight rise in blood pressure."
9. Mann talking with his colleagues in his lab
10. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"Hopefully what it will mean for the patient is that treatment will be carefully controlled by a psychiatrist or somebody who knows something about depression and can assess them and determine how many treatments they need, how often they need the treatments. Do they need one treatment. Do they need two treatments a week, for a while? Where does other medication play a role? All of this will be improved thanks to the approval of the s-ketamine."
11. Mann talking with his colleagues in his lab
12. SOUNDBITE (English) Dr. John Mann, MD, Professor, Columbia University Department of Psychiatry:
"On the other hand, we don't have a very good idea of the long term safety of repeated administrations of ketamine and it does have a theoretical potential for abuse. And so, you know, people vary as to how many doses they want to give and how conservative they are. Here, our view is that obviously you want to use the fewest doses that you can in order to get the best benefit for the patient and you certainly want to have an, we believe, you should have an endpoint."
13. Mann talking with his colleagues in his lab
STORYLINE:
US health officials have approved a medication related to the mind-altering drug ketamine as a new option for patients with severe depression.
The Food and Drug Administration on Tuesday cleared the inhalable drug for patients who have failed to find relief with older antidepressants.
The new drug from Johnson & Johnson acts on different brain chemicals than decades-old antidepressants like Prozac. When it works, the new drug takes effect almost instantly.
The FDA will require J&J to track patients to better understand the drug's safety and effectiveness.
The medication is a chemical cousin of ketamine, a drug long used in surgery that was adopted as an illegal party drug in the 1990s. It's one of several psychedelic drugs that are being reconsidered for depression.
===========================================================
Clients are reminded:
(i) to check the terms of their licence agreements for use of content outside news programming and that further advice and assistance can be obtained from the AP Archive on: Tel +44 (0) 20 7482 7482 Email: info@aparchive.com
(ii) they should check with the applicable collecting society in their Territory regarding the clearance of any sound recording or performance included within the AP Television News service
(iii) they have editorial responsibility for the use of all and any content included within the AP Television News service and for libel, privacy, compliance and third party rights applicable to their Territory.

For All Latest Updates

TAGGED:

Copyright © 2024 Ushodaya Enterprises Pvt. Ltd., All Rights Reserved.